This information is intended for use by health professionalsLUMIGAN 0.3 mg/mL eye drops, solution, in single-dose containerReduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension in adults (as monotherapy or as adjunctive therapy to beta-blockers). Limited experience is available in patients with open-angle glaucoma with pseudoexfoliative and pigmentary glaucoma, and chronic angle-closure glaucoma with patent iridotomy.No clinically relevant effects on heart rate and blood pressure have been observed in clinical trials.The safety and efficacy of LUMIGAN in children aged 0 to 18 years has not been established.Bimatoprost penetrates the human cornea and sclera well Bimatoprost is moderately distributed into body tissues and the systemic volume of distribution in humans at steady-state was 0.67 l/kg. These color changes, usually an increase in brown pigment, occur slowly and you may not notice them for months or years. Hypotrichosis of the Eyelashes. The increased iris pigmentation appears to be caused by increased stimulation of melanin production in melanocytes and not by an increase in melanocyte number. The plasma protein binding of bimatoprost is approximately 88%. Animal studies have shown reproductive toxicity at high maternotoxic doses (see section 5.3).LUMIGAN should not be used during pregnancy unless clearly necessary.It is unknown whether bimatoprost is excreted in human breast milk. This dose is at least 22 times higher than an accidental dose of the entire content of a pack of LUMIGAN 0.3 mg/mL single-dose (30 x 0.4 mL single-dose containers; 12 mL) in a 10 kg child. Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS; LUMIGAN: BIMATOPROST: 0.01%: SOLUTION/DROPS;OPHTHALMIC: Prescription: None Yes: Yes: Approval Date(s) and History, Letters, Labels, Reviews for NDA 022184.

Any unused solution should be discarded immediately after use.The safety and efficacy of LUMIGAN in children aged 0 to 18 years has not yet been established.LUMIGAN has not been studied in patients with renal or moderate to severe hepatic impairment and should therefore be used with caution in such patients. LUMIGAN Savings, Coupons and Information. What is Lumigan Eyedrops Lumigan Eyedrops ® (bimatoprost ophthalmic solution) 0.03% LUMIGAN ® (bimatoprost ophthalmic solution) 0.03% is a synthetic prostamide analog with ocular hypotensive activity. These doses resulted in systemic exposures of at least 33- or 97-times higher, respectively, than the intended human exposure. Call your pharmacist for new medicine.Tell your doctor right away if you have an eye injury or eye infection, or if you plan to have eye surgery.Store this medicine at cool room temperature, away from moisture and heat. There is a potential for hair growth to occur in areas where LUMIGAN solution comes repeatedly in contact with the skin surface.

It’s a once-a-day treatment you apply topically to the base of your upper eyelashes. On combining the data from phase III monotherapy and adjunctive LUMIGAN 0.3 mg/mL (multi-dose formulation) usage, the most frequently reported adverse reactions were: A contaminated dropper can infect your eye, which could lead to serious vision problems.Do not use Lumigan eye drops if the liquid has changed color or has particles in it. Irvine, CA; Allergan, Inc.;2010 March. Bimatoprost is a potent ocular hypotensive agent.

Conjunctival hyperaemia, growth of eyelashes, and eye pruritus were statistically significantly higher with bimatoprost than with latanoprost, however, the discontinuation rates due to adverse events were low with no statistically significant difference.Compared to treatment with beta-blocker alone, adjunctive therapy with beta-blocker and LUMIGAN 0.3 mg/mL (multi-dose formulation) lowered mean morning (08:00) intraocular pressure by -6.5 to -8.1 mmHg. • ocular pruritus in up to 14% of patients in the first year with the incidence of new reports decreasing to 3% at 2 years and 0% at 3 years. 5.1 Pigmentation . Lumigan may contain a preservative that can discolor soft contact lenses.
Continue typing to refine. If LUMIGAN 0.3 mg/mL single-dose is accidentally ingested, the following information may be useful: In short term oral (by gavage) mouse and rat studies, doses up to 100 mg/kg/day of bimatoprost did not produce any toxicity. Follow all directions on your prescription label. LUMIGAN ® 0.01%. • growth of eyelashes in up to 45% in the first year with the incidence of new reports decreasing to 7% at 2 years and 2% at 3 years Available for Android and iOS devices. LUMIGAN should be used with caution in patients with a prior history of significant ocular viral infections (e.g. After twice daily dosing of LUMIGAN 0.3 mg/mL, the mean AUCEffects in non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.Monkeys administered ocular bimatoprost concentrations of ≥0.3 mg/mL daily for 1 year had an increase in iris pigmentation and reversible dose-related periocular effects characterised by a prominent upper and/or lower sulcus and widening of the palpebral fissure.

Interestingly, using Lumigan more frequently than once a day actually makes it less effective. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.punctate keratitis, eye irritation, foreign body sensation, dry eye, eye pain, eye pruritus, growth of eyelashes, eyelid erythemaasthenopia, conjunctival oedema, photophobia, lacrimation increased, iris hyperpigmentation, blurred vision, eyelid pruritus, eyelid oedemaasthma, asthma exacerbation, COPD exacerbation and dyspnoeaHypersensitivity reaction including signs and symptoms of eye allergy and allergic dermatitisIn clinical studies, over 1800 patients have been treated with LUMIGAN 0.3 mg/mL (multi-dose formulation). This site does not dispense medical advice or advice of any kind.